Journal Information
Vol. 20. Issue 1.
Pages 1-7 (January 2024)
Share
Share
Download PDF
More article options
ePub
Vol. 20. Issue 1.
Pages 1-7 (January 2024)
Original Article
CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis
CXCL10 como biomarcador de enfermedad pulmonar intersticial en pacientes con artritis reumatoide
Yasmine S. Makarema,
Corresponding author
yasmine.saad@aun.edu.eg

Corresponding author.
, Elzahraa A. Ahmeda, Marwa Makboulb, Shimaa Farghalyb, Naima Mostafaa, Randa A. El Zohnec, Samar H. Gomaa
a Rheumatology & Rehabilitation Department, Faculty of Medicine, Assiut University, Assiut, Egypt
b Radio-diagnosis Department, Faculty of Medicine, Assiut University, Assiut, Egypt
c Clinical Pathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (6)
Table 1. Baseline and clinical characteristics of RA patients with and without ILD (n=73).
Table 2. DAS28, pulmonary function test, HRCT, MHAQ, and laboratory characteristics of RA patients with and without ILD (n=73).
Table 3. The correlation between CXCL10 biomarker and demographic and clinical details of RA-ILD cases (n=33).
Table 4. Comparison of the CXCL10 means according to DAS categories among RA-ILD patients (n=33).
Table 5. The best cut off, sensitivity and specificity for RA-ILD detection by CXCL0 biomarker (n=73).
Table 6. Univariate and multivariate logistic regression analysis for prediction of RA-ILD by different laboratory data (n=73).
Show moreShow less
Abstract
Introduction

Pulmonary involvement is a frequent and serious rheumatoid arthritis (RA) manifestation that affects 60%–80% of patients. CXCL10 is an inflammatory chemokine that regulates different biological responses, such as chemotaxis, angiogenesis, and inflammation.

Aim

This study aimed to identify the role of CXCL10 as a peripheral blood marker of RA-ILD and its correlation with disease activity.

Patients and methods

This cross-sectional study included 73 patients with RA (33 with ILD and 40 without ILD). Pulmonary function tests and high-resolution computed tomography were performed. Blood samples were taken for complete blood count and blood chemistry analysis, and human interferon-inducible protein 10 (IP-10/CXCL10) level. Statistical Package for the Social Sciences (version 22) was used for all statistical calculations.

Results

The serum CXCL10 level and patient age (r=.393, p=.024), disease duration (r=.756, p<0.001), erythrocyte sedimentation rate (r=.516, p=.002), C-reactive protein (r=.539, p=.001), and rheumatoid factor (r=.663, p<.001) revealed a significant positive correlation. Furthermore, the Modified Health Assessment Questionnaire (r=−.418, p=.015) revealed a significant negative correlation. Patients with RA-ILD show significantly higher CXCL10 than those without ILD (p<.001).

Conclusion

CXCL10 is a useful RA disease activity biomarker and is an RA-ILD-sensitive biomarker, also CXCL10 is a significant predictor for development of RA-ILD.

Keywords:
Rheumatoid arthritis
Interstitial lung disease
Inflammatory chemokine
CXCL10
Resumen
Introducción

La afección pulmonar es una manifestación frecuente y grave de la artritis reumatoide (AR) que afecta al 60-80% de los pacientes. CXCL10 es una quimiocina inflamatoria que regula diferentes respuestas biológicas, como la quimiotaxis, la angiogénesis y la inflamación.

Propósito

Este estudio tuvo como objetivo identificar el papel de CXCL10 como marcador en sangre periférica de RA-ILD y su correlación con la actividad de la enfermedad.

Pacientes y métodos

Estudio transversal que incluyó a 73 pacientes con AR (33 con EPI y 40 sin EPI). Se realizaron pruebas de función pulmonar y tomografía computarizada de alta resolución. Se tomaron muestras de sangre para hemograma completo y análisis de química sanguínea y el nivel de proteína 10 inducible por interferón humano (IP-10/CXCL10). Se utilizó el paquete estadístico para las ciencias sociales (versión 22) para todos los cálculos estadísticos.

Resultados

El nivel sérico de CXCL10 y la edad del paciente (r=0,393, p=0,024), la duración de la enfermedad (r=0,756, p<0,001), la velocidad de sedimentación globular (r=0,516, p=0,002), la proteína C reactiva (r=0,539, p=0,001) y el factor reumatoide (r=0,663, p<0,001) revelaron una correlación positiva significativa. Además, el Cuestionario de Evaluación de la Salud Modificado (r=−0,418, p=0,015) reveló una correlación negativa significativa. Los pacientes con RA-ILD muestran un CXCL10 significativamente mayor que aquellos sin ILD (p<0,001).

Conclusión

CXCL10 es un biomarcador útil de la actividad de la enfermedad de AR y es un biomarcador sensible a AR-ILD, también CXCL10 es un predictor significativo para el desarrollo de AR-ILD.

Palabras clave:
Artritis reumatoide
Enfermedad pulmonar intersticial
Quimiocina inflamatoria
CXCL10

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?